Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Antitumoral Activity and Safety of AEZS-108 (AN-152), a LHRH Agonist Linked Doxorubicin, in Women With LHRH Receptor Positive Gynecological Tumors.

Next Previous
X
Search
Trial Profile

Antitumoral Activity and Safety of AEZS-108 (AN-152), a LHRH Agonist Linked Doxorubicin, in Women With LHRH Receptor Positive Gynecological Tumors.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zoptarelin doxorubicin (Primary)
  • Indications Endometrial cancer; Ovarian cancer
  • Focus Therapeutic Use
  • Sponsors AEterna Zentaris Inc

    • Most Recent Events

    • 04 Feb 2014 Results have been published in the International Journal of Gynecological Cancer according to an AEterna Zentaris media release. Results were also reported in the media release.
    • 14 Sep 2011 Final results in patients with endometrial cancer were presented at the 17th International Meeting of the European Society of Gynaecological Oncology (ESGO).
    • 18 Jul 2011 Status changed from active, no longer recruiting to completed, according to information in an Aeterna Zentaris media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top